AXSM Earnings

AXSM reported its earnings on 2026-02-23, showcasing a revenue of 196.00M against an estimate of 193.01M, resulting in a 1.55% surprise. The EPS was -0.71, surpassing the expected -0.7 by -1.43%. The stock experienced a -4.88% price change on the earnings day and a -11.17% change over the next five days, reflecting market reactions to the results.

Following AXSM's earnings announcement on 2026-02-23, the stock price moved by -4.88% on the day of the release. Over the subsequent five days, it saw a -11.17% change. Historically, AXSM's stock price tends to shift by an average of -1.08% in the 10 days leading up to earnings and -0.09% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate AXSM's annual revenue to reach 188.33M, while the EPS is projected at -0.55. These estimates reflect recent revisions, with revenue estimates revised downward by -0.03% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between AXSM's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.03%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AXSM's stock price typically moves by -1.08% in the 10 days before its earnings and -0.09% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.55 and revenue of 188.33M.

The earnings call highlights strong prescription growth for key products like AUVELITY and SUNOSI, successful launch of SYMBRAVO, and promising pipeline developments. The Q&A reveals positive analyst sentiment towards growth drivers and market opportunities, despite some unclear management responses. The strategic plan indicates expansion and potential new approvals, suggesting future growth. The market cap of $3.8 billion suggests moderate sensitivity to news. Overall, the combination of strong current performance and optimistic future guidance justifies a positive stock price outlook over the next two weeks.